- 115
- Episodes
- 2
- Ratings
- Weekly
- Cadence
- 2025
- First episode
About Dr. Paika Podcast
Welcome to the Dr. Paika Podcast — where medicine, fitness, and humanity come together. Hosted by Dr. Mohammed K. Paika, M.D., double board-certified in obesity & internal medicine with over two decades of hospital experience, this show dives deep into the science of health, obesity, longevity, and mindset — but with compassion, not complexity. From hospital medicine to the gym floor, from patient care to personal growth — every episode blends real clinical insight with practical, inspiring stories that help you live better and think deeper. 💡 Topics include: Obesity & metabolic health Longevity & fitness Nutrition & preventive medicine Doctor insights from 20+ years in hospitals across the US! Mindset, mental health, and motivation 🎧 Subscribe for weekly conversations that are honest, empowering, and rooted in science — all from a doctor who believes medicine should heal the mind and body.
- Publisher
- Mohammed Paika
- Category
- health & fitness · health & fitness
- Language
- en
- Explicit
- No
- First episode
- 8 Nov 2025
- Latest episode
- 20 Oct 2026
Latest episodes
115 episodes in the feed.
20 Oct 2026
Microdosing Zepbound & Ozempic: How Low Can You Go and Still Keep the Weight Off? (Doctor Explains)
#GLP1 #Microdosing #Zepbound #Ozempic #WeightLossMaintenance Microdosing Zepbound & Ozempic: How Low Can You Go and Still Keep the Weight Off? You hit your goal weight. Now the question is: do you have to stay on this dose forever? More and more people are cutting their GLP-1 dose to a fraction or stretching their shots to every 10 to 14 days, hoping to save money, cut side effects, and keep the weight off. I'm Dr. Mohammed Paika, a board-certified internal medicine and obesity medicine physician and practicing hospitalist. In this video I break down what the research actually shows about lower-dose GLP-1 maintenance, and what it doesn't show yet. 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost. https://www.drmohammedpaika.com 📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity. https://www.drmohammedpaika.com/newsletter TIMESTAMPS 0:00 Do I have to stay on this dose forever? 1:24 The rebound: what happens when you stop 2:49 Why microdosing is trending now 4:01 What is microdosing? The minimal effective dose 5:02 Two approaches: dose reduction vs. interval spacing 6:01 What happens at lower doses 7:35 Muscle preservation 9:14 What the evidence says: SURMOUNT-MAINTAIN 12:03 Why the weight comes back: the set point 13:35 Why people want a lower dose: cost, supply, side effects 14:16 The 4 risks of going too low 17:06 My step-down framework 18:38 How low can you go? The bottom line REFERENCES 1. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. 2. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48. 3. SURMOUNT-4 post hoc analysis of weight regain. JAMA Intern Med. 2025. 4. Evidation. Real-world GLP-1 dosing behaviors (preliminary survey). December 2025. 5. Bickel CS, Cross JM, Bamman MM. Exercise dosing to retain resistance training adaptations in young and older adults. Med Sci Sports Exerc. 2011;43(7):1177-1187. 6. Wegovy (semaglutide), Ozempic (semaglutide) and Zepbound (tirzepatide) US prescribing information. 7. Hackensack Meridian Health. Is microdosing GLP-1s safe? May 2026. 8. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-1439. 9. Nauck MA, et al. Rapid tachyphylaxis of the GLP-1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-1565. 10. O'Neil PM, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss (phase 2). Lancet. 2018;392:637-649. 11. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232. 12. Wilding JPH, et al. STEP 1 body composition (DXA) substudy. J Endocr Soc. 2021;5(Suppl 1):A16-A17. 13. Look M, et al. SURMOUNT-1 body composition (DXA) substudy. Diabetes Obes Metab. 2025. 14. SURMOUNT-MAINTAIN. Tirzepatide maximum dose vs. 5 mg vs. placebo for weight maintenance. Lancet. May 2026. 15. Gudbergsen H, et al. Semaglutide with a digital weight-management program in Denmark (Embla), lowest effective dose. 2025. 16. Embla semaglutide tapering study. European Congress on Obesity. 2024. 17. ClinicalTrials.gov NCT07783854. Randomized dose-tapering regimen of semaglutide for weight-loss maintenance. 18. Eli Lilly. ATTAIN-MAINTAIN topline results (orforglipron). December 2025. 19. Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597-1604. 20. Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016;24(8):1612-1619. 21. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. 2025. 22. Eli Lilly. Zepbound KwikPen instructions for use and FAQ (priming). 2026. 23. US FDA. Dosing errors with compounded semaglutide. July 26, 2024. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
17 Oct 2026
Splitting Your Ozempic or Mounjaro Dose: Is It Safe? (Doctor Explains)
#Ozempic #Mounjaro #GLP1 #Tirzepatide #WeightLossDoctor Should you split your weekly Ozempic, Wegovy, Mounjaro, or Zepbound shot into two smaller doses? Lots of you have asked me about this in the comments. People split their dose to ease the nausea in the first few days and keep food noise down late in the week. In this video, I explain what the pharmacokinetics predict, what the clinical trials did and didn’t test, and the hidden risks most people never hear about. As an obesity medicine physician, I walk you through half-life, steady state, peak and trough levels, and a simple model of what splitting does to your drug levels. Then I cover the safer, approved ways your doctor can smooth out your week instead. 📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity. https://www.drmohammedpaika.com/newsletter 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost. https://www.drmohammedpaika.com ⚠️ This video is for education only and is not personal medical advice. Don’t change your dose, your schedule or your device without talking to the clinician who prescribes it. TIMESTAMPS 0:00 Should you split your weekly GLP-1 dose? 1:17 Why people split their dose: the peak and the trough 2:56 Half-life and steady state 3:27 What splitting does to your drug levels 5:11 Side effects: the peak or the dose increase? 6:09 What the clinical trials actually tested 7:52 Plausible vs. proven 8:21 Hidden risks: pens and vials 9:16 Compounded vials and dosing errors 10:44 Strategy 1: Slow the titration 11:23 Strategy 2: Find your lowest effective dose 11:56 Strategy 3: Eat around injection day 12:35 Strategy 4: Timing and short-term support 12:58 Strategy 5: Change the molecule 13:45 The verdict 14:14 3 questions for your doctor REFERENCES Wegovy (semaglutide) US Prescribing Information, Novo Nordisk. https://www.novo-pi.com/wegovy.pdf Zepbound (tirzepatide) US Prescribing Information, Eli Lilly. https://medlibrary.org/lib/rx/meds/zepbound/page/5/ Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002. Wharton S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg. Diabetes Obes Metab. 2022;24:94-105. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. Aronne LJ, et al. Tirzepatide vs. semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025. O’Neil PM, et al. Semaglutide vs. liraglutide and placebo for weight loss (phase 2). Lancet. 2018;392:637-649. Frias JP, et al. Tirzepatide dose-escalation regimens. Diabetes Obes Metab. 2020;22:938-946. Huang KP, et al. Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature. 2024;632:585-593. Lau J, et al. Discovery of the once-weekly GLP-1 analogue semaglutide. J Med Chem. 2015;58:7370-7380. Cengiz A, et al. Alternative dosing regimens of GLP-1 receptor agonists. Diabetes Obes Metab. 2025;27:2251-2258. Ji L, et al. GZR18 once-weekly or bi-weekly dosing: phase 1b/2a trial. Cell Rep Med. 2026;7:102743. FDA. Dosing errors associated with compounded injectable semaglutide (July 2024). https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded ISMP. Errors possible when microdosing (counting clicks) to dose weight loss medicines (2025). https://www.consumermedsafety.org/safety-articles/errors-possible-when-microdosing-counting-clicks-to-dose-weight-loss-medicines Lilly Medical: Zepbound single-dose vial and KwikPen guidance. https://medical.lilly.com America’s Poison Centers semaglutide call data, as reported by CNN/ABC7 (Dec 2023). https://abc7ny.com/fda-poison-control-centers-weight-loss-drug-diabetes/14178159/ Foundayo (orforglipron) US Prescribing Information, Eli Lilly. Ryan H, et al. OxyContin’s 12-hour problem. Los Angeles Times. 2016. Modeled peak and trough figures come from a simple one-compartment model built on label half-lives. They are illustrative estimates, not blood levels measured in a trial. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
15 Oct 2026
How to REMOVE Food Noise (It’s Not Willpower) | Doctor Explains
#FoodNoise #GLP1 #Ozempic #WeightLoss #ObesityMedicine Can't stop thinking about food, even right after a full meal? That constant chatter has a name: food noise. I explain what it is, why GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound quiet it, and why it often returns when people stop them. You'll learn the 2 drivers behind it, a simple test to tell real hunger from food noise, and 9 evidence-based strategies to turn it down, with or without medication. Every claim is referenced below. 📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity. https://www.drmohammedpaika.com/newsletter 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost. https://www.drmohammedpaika.com TIMESTAMPS 0:00 Can't stop thinking about food? 1:32 Food noise vs. real hunger 2:02 Why GLP-1s made food noise famous 2:41 What happens when you stop semaglutide 3:02 Your brain's 2 appetite systems 4:13 Driver 1: Physical 4:24 Pattern 1: Eating too little, too early 7:20 Driver 2: Psychological 7:30 Trigger 1: Habit (the Netflix effect) 9:02 How sleep and stress turn up the volume 9:29 The plain-food test: hunger or noise? 9:57 9 strategies to quiet food noise 10:07 1. Protein-forward breakfast 10:31 2. Eat your carbs last 10:58 3. Protect your sleep 11:16 4. Edit your food cues 11:39 5. Plan and prep once a week 13:27 Your 7-day experiment 13:42 When food noise is still loud: GLP-1 medications 14:15 4 important caveats 15:11 When it's more than noise REFERENCES 1. Hayashi 2023, Nutrients: https://pubmed.ncbi.nlm.nih.gov/38004203/ 2. Blundell 2017, Diabetes Obes Metab: https://pmc.ncbi.nlm.nih.gov/articles/PMC5573908/ 3. van Bloemendaal 2014, Diabetes 63(12):4186 4. Wilding 2022, Diabetes Obes Metab: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542252/ 5. Lutter 2009, J Nutr: https://pubmed.ncbi.nlm.nih.gov/19176746/ 6. Berridge 2009, Physiol Behav: https://pmc.ncbi.nlm.nih.gov/articles/PMC2717031/ 7. Boswell 2016, Obes Rev: https://canlab.yale.edu/sites/default/files/boswel-kober_2016_obesityreviews.pdf 8. Wood & Neal 2007, Psychol Rev 114(4):843 9. Keys 1950, The Biology of Human Starvation (Minnesota Starvation Experiment) 10. Sumithran 2011, NEJM: https://pubmed.ncbi.nlm.nih.gov/22029981/ 11. Rolls 2017, Nutr Bull: https://pubmed.ncbi.nlm.nih.gov/29151813/ 12. Dennis 2010, Obesity: https://pubmed.ncbi.nlm.nih.gov/19661958/ 13. World Health Organization 2023, Guideline on non-sugar sweeteners (May 15, 2023) 14. Ludwig 1999, Pediatrics: https://pubmed.ncbi.nlm.nih.gov/10049982/ 15. Lennerz 2013, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/23803881/ 16. Weigle 2005, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/16002798/ 17. Hall 2019, Cell Metab: https://pubmed.ncbi.nlm.nih.gov/31105044/ 18. Leidy 2015, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/25926512/ 19. Neal et al. 2011, Pers Soc Psychol Bull 37(11):1428 20. Tomova 2020, Nat Neurosci: https://dspace.mit.edu/handle/1721.1/138313 21. Spiegel 2004, Ann Intern Med: https://pubmed.ncbi.nlm.nih.gov/15583226/ 22. Hoertel 2014, Nutr J: https://nutritionj.biomedcentral.com/articles/10.1186/1475-2891-13-80 23. Leidy 2013, Am J Clin Nutr: https://pmc.ncbi.nlm.nih.gov/articles/PMC3718776/ 24. Tasali 2022, JAMA Intern Med: https://pubmed.ncbi.nlm.nih.gov/35129580/ 25. Hunter 2018, Appetite: https://pubmed.ncbi.nlm.nih.gov/29183701/ 26. Ducrot 2017, Int J Behav Nutr Phys Act: https://pubmed.ncbi.nlm.nih.gov/28153017/ 27. Lieberman 2007, Psychol Sci: https://pubmed.ncbi.nlm.nih.gov/17576282/ 28. Zaccaro 2018, Front Hum Neurosci: https://pubmed.ncbi.nlm.nih.gov/30245619/ 29. Gollwitzer & Sheeran 2006, Adv Exp Soc Psychol 38:69 30. Taylor & Oliver 2009, Appetite 52(1):155 31. Ledochowski 2015, PLoS One: https://pmc.ncbi.nlm.nih.gov/articles/PMC4356559/ 32. Buffey 2022, Sports Med: https://pubmed.ncbi.nlm.nih.gov/35147898/ 33. Wilding 2021, NEJM (STEP 1): https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 34. Hudson 2007, Biol Psychiatry: https://pubmed.ncbi.nlm.nih.gov/16815322/ 35. Tataranni 1996, Am J Physiol: https://pubmed.ncbi.nlm.nih.gov/8770026/ 36. Shukla 2015, Diabetes Care: https://pmc.ncbi.nlm.nih.gov/articles/PMC4876745/ ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
- Apple Podcasts (US)
- 5.0 / 5
- 2 ratings
Contact Dr. Paika Podcast
- Guest appearances
- Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Dr. Paika Podcast?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show
Podcast research with Pod Engine